Skip to main content
x
About searching

Search results

  1. ESMO 2023 – Merck makes its KRAS entrance

    ESMO 2023 – Merck makes its KRAS entrance … in TPS ≥50%; TPS=tumour proportion score; *reported at ESMO 2023; **reported at ESMO-IO Dec 2022. …

    - 10/22/2023 - 14:04

  2. ESMO 2023 – not so fast, Welireg

    ESMO 2023 – not so fast, Welireg Full …

    - 10/22/2023 - 16:00

  3. ESMO 2023 – GSK sets up Pfizer battle in B7-H4

    ESMO 2023 – GSK sets up Pfizer battle in B7-H4 … inhibitor 6 Ph1 China study in solid tumours ESMO 2023: 29% ORR across TNBC pts; 27-33% ORR at target … Monomethyl auristatin E 4 Ph1 in solid tumours ESMO 2023 abstract: responses in breast (7/25), ovarian …

    - 12/20/2023 - 14:07

  4. ESMO 2023 – sabestomig has it all to do in TIM-3

    ESMO 2023 – sabestomig has it all to do in TIM-3 …

    - 10/21/2023 - 18:04

  5. ESMO 2023 – Amgen’s Steap1 project spurs cautious optimism

    ESMO 2023 – Amgen’s Steap1 project spurs cautious …

    - 10/21/2023 - 15:55

  6. ESMO 2023 – Amgen keeps tarlatamab filing plans under wraps

    ESMO 2023 – Amgen keeps tarlatamab filing plans under … DLL3 positivity 40% ORR with 10mg dose (40/100 pts) at ESMO 2023, responses seen regardless of DLL3 expression; …

    - 10/21/2023 - 10:50

  7. ESMO 2023 – Perla gives Jemperli combos more backing

    ESMO 2023 – Perla gives Jemperli combos more backing …

    - 10/21/2023 - 11:10

  8. After failing to get Seagen Merck turns to Daiichi

    … TROP2 4 Tropion-Lung01 & Tropion-Breast01 data at ESMO 2023 Astra paid $1bn up front, $1bn due in …

    - 10/21/2023 - 15:55

  9. ESMO 2023 – Jiangsu Hengrui sets a low bar in KRAS G12D inhibition

    ESMO 2023 – Jiangsu Hengrui sets a low bar in KRAS G12D …

    - 10/18/2023 - 16:33

  10. ESMO 2023 – duelling PD-1 drugs

    ESMO 2023 – duelling PD-1 drugs Quick …

    - 10/18/2023 - 15:52